

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 4, 2023**

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction
of incorporation)

001-39082

(Commission File Number)

45-5401931

(IRS Employer
Identification No.)

**2222 Ponce de Leon Blvd, Floor 3
Coral Gables, FL**

(Address of principal executive offices)

33134

(Zip Code)

Registrant's telephone number, including area code: **(786) 629 1376**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, \$0.001 par value per share	RLMD	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 4, 2023, the Company updated its corporate presentation, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation dated October 4, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 4, 2023

RELMADA THERAPEUTICS, INC.

By: /s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer



Targeting Major Advances in the Treatment of CNS Disorders

October 4th, 2023

Disclosures

Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," "projected" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. Statements regarding future action, future performance and/or future results, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company's formulations and products and regulatory filings related to the same may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission ("SEC") filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company's filings for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and financial performance.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's Form 10-K, 10-Q and 8-K reports.

Investment highlights

CNS focused, with lead program for REL-1017, a novel MOA, in Phase 3 for Major Depressive Disorder (MDD)

Compelling Phase 2 data indicating the robust therapeutic effect of REL-1017 for MDD

Efficacy and safety profile of REL-1017 potentially address limitations of current MDD treatments options

Phase 3 program underway with two ongoing Phase 3 trials for REL-1017 as Adjunctive Treatment for MDD

Highly experienced clinical team with a successful track record advancing CNS programs through NDA approval

CNS= Central Nervous System


©2023 Relmada - All rights reserved | 3

**The unique profile of
esmethadone (REL-1017)
addresses the limitations
of current treatment
options for MDD**



©2023 Relmada - All rights reserved | 4

The prevalence of depression



*Rx = prescription

1. Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS) 2019 National Survey on Drug Use and Health; 2. Decision Resources Group Unipolar Depression 2020 report; 3. WHO Depression Fact Sheet

©2023 Reimada - All rights reserved | 5

Limitations of current treatments for MDD

Limited efficacy


~65% MDD patients do not respond to first antidepressant treatment¹

Slow onset of action

Standard antidepressants, even when effective, may take up to 8 weeks to reach efficacy²

Safety and tolerability challenges

Side effects of atypical antipsychotics approved as adjunctive treatments for MDD include tardive dyskinesia, metabolic syndrome, cognitive impairment and stroke³



MDD = major depressive disorder

1. Trivedi MH, et al. Am J Psychiatry. 2006;163:28-40; 2. Ashton AK, et al. Curr Ther Res. 2005;66(2):97-106; 3. US Prescribing Information, brexpiprazole, quetiapine, aripiprazole

©2023 Reimada - All rights reserved | 6

Unique profile of esmethadone (REL-1017) addresses limitations of current treatments

Potential as a rapid, oral, once-daily antidepressant for MDD, if approved

Novel Mechanism of Action: preferential targeting of NMDAR channels potentially associated with MDD^{1,2,3}

Clinical data has demonstrated:

- Robust, rapid, and sustained statistically significant antidepressant effects on all tested scales⁴
- Rapid onset: significant efficacy effects by Day 4⁴
- Favorable safety and tolerability profile consistent across all studies^{4,5,6}: no opioid and no psychotomimetic adverse events and no metabolic side effects^{4,5,6}
- Orally administered, once-daily tablet

MDD = major depressive disorder; NMDAR = N-methyl-D-aspartate receptor


1. Bettini E et al. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors. *Pharmaceuticals (Basel)*. 2022;15(8):997; 2. Bettini E et al. The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin. *Pharmaceuticals (Basel)*. 2022;15(7):882; 3. Stahl SM et al. Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling. *Int J Mol Sci*. 2022;23(20); 4. Fava M et al. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. *Am J Psychiatry*. 2022;179(2):122-131; 5. Bernstein et al. Characterization of the Safety and Pharmacokinetic Profile of D-Methadone, a Novel N-Methyl-D-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies. *J Clin Psychopharmacol*. 2019;39(3):226-237; 6. Reimada data on file

©2023 Reimada - All rights reserved | 7

Esmethadone¹ (REL-1017) is a novel NMDA receptor antagonist

NMDA: N-methyl-D-aspartate
GluN2D: Glutamate NMDA receptor with 2D subunits
BDNF: brain-derived neurotrophic factor
MDD: major depressive disorder

Receptor, synapses and brain images are artistic renditions



Esmethadone preferentially blocks tonically hyperactive GluN2D receptor subtypes², potentially increasing BDNF³, decreasing neuroinflammation⁴ and restoring physiological neuroplasticity^{5,6,7}.

Synaptic spines increase in size within 24 hours of administration⁸. Esmethadone is devoid of dissociative effects⁹, has no meaningful abuse potential¹⁰ and is administered orally once-daily.

1. Esmethadone is a promising non-dissociative NMDAR antagonist antidepressant (Fava 2023)
2. Esmethadone preferentially targets tonically hyperactive GluN2D receptors (Bettini 2022A)
3. Esmethadone increases BDNF release (Fogaca 2019; De Martin 2021)
4. Esmethadone reduces calcium influx induced by quinolinic acid (Bettini 2022B)
5. Esmethadone restores impaired neuroplasticity (Fogaca 2019; Stahl 2022)
6. Impaired neuroplasticity and neuroinflammation may be central to the pathophysiology of MDD (Cooper 2023)
7. Esmethadone is a promising neuroplastogen[®] that could transform the current treatment of MDD (Cooper 2023)

8. A single dose of esmethadone increases synaptic spines (Fogaca 2019)
9. Esmethadone does not cause dissociative effects (Shram 2023)
10. Esmethadone differs pharmacologically from levomethadone because it is devoid of clinically relevant opioid activity. Esmethadone has no meaningful abuse potential in healthy subjects (Bernstein 2019), patients with MDD (Fava 2022) and recreational substance users (Shram 2023)

©2023 Reimada - All rights reserved | 8

The clinical development of esmethadone (REL-1017) is steadily progressing as Adjunctive Treatment for MDD



©2023 Relmada - All rights reserved | 9

Esmethadone (REL-1017) clinical development status

All non-clinical studies have been successfully completed

All Phase 1 studies and Human Abuse Potential studies (HAPs) have been successfully completed

The open-label 12-month study has been successfully completed

The Phase 3 development program is ongoing; Reliance I (study 301) has been completed, Reliance II (study 302) and Relight (study 304) are currently in progress

Stability testing of primary packaging has been completed, and production at scale has been validated

©2023 Relmada - All rights reserved | 10

**Data from the Phase 1,
Phase 2, and Human
Abuse Potential studies
indicate favorable safety
and tolerability of
esmethadone (REL-1017)**



©2023 Relmada - All rights reserved | 11

All Phase 1 studies have been successfully completed

- Multiple Ascending Dose (MAD) study
- Single Ascending Dose (SAD) study
- Oxycodone Human Abuse Potential (HAP) study
- Intravenous Ketamine Human Abuse Potential (HAP) study
- Renal Impairment study and Hepatic Impairment study
- Drug-Drug Interaction (DDI) study
- Absorption, distribution, metabolism, excretion (ADME) study

©2023 Relmada - All rights reserved | 12

The Human Abuse Potential studies have been successfully completed and indicate no abuse potential of REL-1017

The results of experimental studies predictive of human abuse potential ¹ and the results of human abuse potential studies in recreational opioid users ² and in recreational ketamine users ³ indicate no meaningful abuse potential and support the DEA statement below:




“The *d*-isomer lacks significant respiratory depressant action and addiction liability...”

US Drug Enforcement Administration
December 2019 ⁴



1. Henningfield, et al. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Sci Rep 12, 11389 (2022); 2. Shram M, et al., No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant American Society of Clinical Psychopharmacology (ASCP) 2022; 3. Shram M, et al., No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant. American Society of Clinical Psychopharmacology (ASCP) 2022; 4. US DEA Statement on Methadone, December 2019 February 2022

Phase 2 study results: primary efficacy endpoint

REL-1017 25 and 50 mg (Day 1 loading dose 75 and 100 mg, respectively) showed rapid and sustained differences in MADRS change vs. placebo



Phase 2 study efficacy results: response & remission




Day 14: last efficacy assessment, 7 days after last dose of study drug
* p < .05
MADRS=Montgomery-Asberg Depression Rating Scale
Source: Fava et al. Rapid and Sustained Antidepressant Effects of REL-1017 (dextromethadone) as an Adjunctive Treatment for Major Depressive Disorder

The Phase 3 program as
Adjunctive Treatment for
MDD is currently ongoing




Esmethadone (REL-1017) Phase 3 development program



©2023 Relmada - All rights reserved | 17


Reliance I primary efficacy endpoint: REL-1017 showed a clinically meaningful -2.3 MADRS point difference vs. placebo at Day 28 in the full analysis set



Day 28: last efficacy assessment
Total N=227; MADRS=Montgomery-Asberg Depression Rating Scale; Source: Relmada Data on File


©2023 Relmada - All rights reserved | 18

In Reliance I REL-1017 showed a clinically meaningful -3.1 MADRS point difference vs. placebo at Day 28 in the Reliance I per protocol set* (p=0.051)




*Per-Protocol Set: Valid completer, i.e. participants who completed the 28-day treatment and did not have any major protocol deviations impacting the efficacy assessments. This set was analyzed according to the treatment actually received.
Day 28: End of treatment and primary efficacy endpoint
MADRS=Montgomery-Asberg Depression Rating Scale; Source: Relmada Data on File

Reliance I achieved a statistically significant response rate of 40% (p=0.044), and achieved remission rate of 22% (p=0.076) at Day 28 in the full analysis set



Day 28: last efficacy assessment
Total N=227; * p<0.05
MADRS=Montgomery-Asberg Depression Rating Scale; Source: Relmada Data on File



Patient sources: verifiable vs. unverifiable


Verifiable sources

- Past patient at site
- Current patient
- Site database
- HCP referral

Unverifiable sources

- Radio/TV AD
- Banner/Pop AD
- Social media
- Internet search
- Friend
- Recruitment company
- Referral from other patients

Reliance I MADRS10 results for patients from verifiable sources vs unverifiable sources



In Reliance I no serious treatment-related adverse events (AE)* and no opioid like effects were observed

Treatment-related adverse events by preferred term in patients with MDD in the safety analysis set

Variable	Placebo (N=114)		REL-1017 25 mg (N=113)		All patients (N=227)	
	N	%	N	%	N	%
Patients with at least one AE	61	53.5	55	48.7	116	51.1
Patients with at least one treatment-related AE	28	24.6	30	26.5	58	25.6
Patients with at least one serious treatment-related AE	0	0.0	0	0.0	0	0.0
Adverse events occurring in 5% or more patients per treatment arm						
Headache	9	7.9	13	11.5	22	9.7
COVID19	10	8.8	6	5.3	16	7.0
Upper respiratory tract infection	6	5.3	8	7.1	14	6.2
Nausea	5	4.4	8	7.1	13	5.7
Diarrhea	7	6.1	5	4.4	12	5.3
Constipation	7	6.1	3	2.7	10	4.4
Dizziness	2	1.8	7	6.2	9	4.0

AE = adverse event

©2023 Relmada - All rights reserved | 23

REL-1017 displays a favorable safety & tolerability profile and confirms no evidence for meaningful abuse potential across studies

Cardiac safety

No AE related to QTcF prolongation

No increase in suicidality

No signal of drug induced suicidal ideation/behavior measured with C-SSRS¹

No dissociative effects

No signal of drug-induced dissociation measured with CADDs²

No abuse potential

No “drug liking” VAS differences from placebo

No signal of withdrawal measured with SOWS³, COWS⁴ and PWC-20⁵


No MADDERS[®] reports of concern⁶

These Phase 3 results are consistent with safety and tolerability findings from the Phase 2 study

1. C-SSRS: Columbia Suicide Severity Rating Scale; 2. CADDs: Clinician-Administered Dissociative States Scale; 3. SOWS: Subjective Opioid Withdrawal Scale; 4. COWS: Clinical Opiate Withdrawal Scale; 5. PWC-20: Physician Withdrawal Checklist; 6. MADDERS[®]: Misuse, Abuse, and Diversion Drug Event Reporting System

©2023 Relmada - All rights reserved | 24

Reliance-OLS change from baseline by visit in MADRS10 total score, response, and remission rates for the total de novo subjects



OLS = Open-label study; MADRS=Montgomery-Asberg Depression Rating Scale; SD = Standard Deviation; Source: Relmada Data on File

©2023 Relmada - All rights reserved | 25

In Reliance-OLS no serious treatment-related adverse event was observed for all patients (de novo and rollover)

There was no significant safety signal for weight gain, sexual dysfunction, cardiovascular issues, dissociative effects, withdrawal phenomena or abuse liability

Variable	All patients (N=618)	
	N	%
Patients with at least one AE	347	56.1
Patients with at least one treatment-related AE	168	27.2
Patients with at least one serious treatment-related AE	0	0.0
Adverse events occurring in 5% or more patients		
COVID-19	60	9.7
Headache	60	9.7
Upper respiratory tract infection	53	8.6
Nausea	31	5.0
The most common treatment-related adverse events		
Headache	27	4.4
Nausea	25	4.0
Dizziness	15	2.4


Relmada is conducting two Phase 3 trials



Phase 3 studies, currently ongoing in the United States, to evaluate the efficacy and safety of REL-1017 as an adjunctive treatment for MDD

©2023 Relmada - All rights reserved | 27

Three pillars for successful clinical execution



©2023 Relmada - All rights reserved | 28

Reliance II (study 302) trial design for Adjunctive Treatment of MDD



ADJUNCTIVE THERAPY


Primary endpoint:

- Change in MADRS at Day 28

Secondary endpoints:

- Change in MADRS score at Day 7
- Change in CGI-S score at Day 28
- Response Rate at Day 28
- Remission Rate at Day 28

Safety and tolerability assessments



MADRS = Montgomery-Asberg Depression Rating Scale; EAP = expanded access program; MDE = major depressive episode; QD = once daily

©2023 Relmada - All rights reserved | 29

Relight (study 304) trial design for Adjunctive Treatment of MDD



ADJUNCTIVE THERAPY


Primary endpoint:

- Change in MADRS at Day 28

Secondary endpoints:

- Change in MADRS score at Day 7
- Change in CGI-S score at Day 28
- Response Rate at Day 28
- Remission Rate at Day 28

Safety and tolerability assessments



MADRS = Montgomery-Asberg Depression Rating Scale; MDE = major depressive episode; ADT = antidepressant treatment; QD = once daily; EAP = expanded access program

©2023 Relmada - All rights reserved | 30

Data generated for esmethadone (REL-1017) support efficacy, safety, and tolerability for adjunctive treatment of depression

- Phase 2 trial reached significance $p = 0.0122$ (25 mg) for the primary endpoint in the Intent-to-treat (ITT) analysis
- Reliance I, the first adjunctive Phase 3 trial, showed a 40% response rate ($p = 0.044$) in the ITT analysis and 3.1 MADRS-points CFB difference compared with placebo ($p = 0.0510$) in the Per Protocol (PP) analysis
- All studies to date have shown a consistent favorable safety and tolerability profile with no evidence of abuse potential or withdrawal
- Reliance II (study 302) and Relight (study 304) are currently ongoing in the US to evaluate the efficacy of REL-1017 25mg

MADRS = Montgomery-Asberg Depression Rating Scale; CFB = change from baseline

©2023 Relmada - All rights reserved | 31

Corporate information



©2023 Relmada - All rights reserved | 32

Financial overview



*As converted share count of 45.6 MM share as of 06/30/2023

©2023 Reimada - All rights reserved | 33

Through our Neuroplastogen™ Program we are developing a pipeline of molecules with neuroplastic modulating activity for a variety of indications



Novel esmethadone derivatives

We have synthesized a series of novel esmethadone derivatives with NMDAR regulating activity. We are in the process of selecting the most promising candidates to advance into development for the treatment of CNS disorders.



Novel psilocybin formulation and novel psilocybin derivatives

We are developing a novel psilocybin formulation and we are synthesizing psilocybin derivatives with promising activity for the treatment of CNS disorders.

CNS = Central Nervous System; NMDAR = N-methyl-D-aspartate receptor

©2023 Reimada - All rights reserved | 34

Summary

Focus on CNS diseases and lead program in Major Depressive Disorder

- REL-1017 is in Phase 3 for depression, a primary cause of disability worldwide¹
- REL-1017 potentially addresses the limitations of current MDD treatments where 50%–66% of patients do not fully recover on an antidepressant medication², take 4-8 weeks to work, and have significant side effects
- Highly experienced clinical team with CNS focused backgrounds and successful track record of advancing programs through NDA approval

Highly compelling opportunity with esmethadone (REL-1017)

- **Phase 3 program underway** with positive efficacy signals and safety data
- Novel MOA with successful Phase 2 trial in adjunctive MDD that showed statistically significant, robust, rapid, and sustained antidepressant effects with favorable safety and tolerability profile³
- Strong intellectual property estate around REL-1017 with expirations through the mid/late-2030s

Ongoing Phase 3 trials are operationally improved

- Improved clinical trial management
- Quality patient selection
- Careful site selection
- Protocol simplification

CNS= Central Nervous System; MDD = major depressive disorder; MOA = mechanism of action

1. WHO Depression Fact Sheet; 2. Al-Harbi K.S. 2012 *Patient Preference and Adherence*; 3. Fava, et al. Rapid and Sustained Antidepressant Effects of REL-1017 (dextromethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial. 2021

©2023 Relmada - All rights reserved | 35



Thank you